August 15, 2025

FDA Approves Non-Opioid Fibromyalgia Therapy

Tonmya reduces fibromyalgia pain versus placebo in phase 3 trials, offering a non-opioid option with a generally well-tolerated safety profile.

Conexiant

August 15, 2025

Approved: HPV-Targeted Immunotherapy for Recurrent Respiratory Papillomatosis

Standard management has relied on repeated surgical debulking, which does not eradicate underlying HPV infection.

Conexiant

August 12, 2025

FDA Approves First Therapy for Non-cystic Fibrosis Bronchiectasis

Brensocatib (Brinsupri) will offer a new treatment option for patients 12 years and older.

Conexiant

August 12, 2025

Advanced-Practice Providers Filling Rural ER Gaps

Rural emergency rooms across the U.S. are increasingly staffed by physician assistants and nurse practitioners instead of physicians, raising debates over care quality, staffing shortages, and access to emergency services.

KFF Health News

August 11, 2025

FDA Grants Priority Review to Gepotidacin for Gonorrhea

First potential oral treatment for gonorrhea supported by positive phase 3 trial results.

Conexiant

August 11, 2025

FDA OKs Bioequivalent Iron Sucrose for CKD Anemia

The FDA has approved a bioequivalent iron sucrose injection for treating iron deficiency anemia in patients with chronic kidney disease.

Conexiant

August 11, 2025

Why Turning 26 Jeopardizes Health Coverage

A growing number of young Americans lose affordable health insurance at age 26, facing complex Affordable Care Act marketplaces, rising costs, and limited coverage options.

KFF Health News

August 11, 2025

CDC Shooting Deepens Crisis in HIV Prevention

CDC workers describe stalled HIV prevention projects, morale collapse, and heightened safety fears after budget cuts, layoffs, and a deadly shooting at agency headquarters.

KFF Health News

August 06, 2025

New Preventive Option Approved for Pediatric Migraine

The FDA has approved Ajovy (fremanezumab-vfrm) for preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years weighing 45 kg or more, expanding its use beyond adults.

Conexiant